A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

被引：1
|
作者：
von Keudell, Gottfried [1 ,2 ]
Logan, Emma K. [2 ]
Redd, Robert A. [3 ]
Sarosiek, Shayna R. [4 ,5 ]
Branagan, Andrew R. [6 ]
Anderson Jr, Larry D. [7 ]
Dittus, Christopher [8 ]
Treon, Steven P. [5 ]
Castillo, Jorge J. [4 ,9 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA
[4] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Massachusetts Gen Hosp Canc Ctr, Ctr Multiple Myeloma, Boston, MA USA
[7] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[8] Univ North Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206415
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6294 / 6295
页数：2
相关论文
共 50 条
  • [1] Cause-specific mortality in survivors of lymphoplasmacytic lymphoma (LPL) and waldenstrom macroglobulinemia (WM).
    Dalal, Nicole H.
    Dores, Graca
    Curtis, Rochelle E.
    Linet, Martha S.
    Morton, Lindsay M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Treatment Selection and Clinical Outcomes in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia (LPL/WM) - a Single Center Analysis
    Tariq, Muhammad Junaid
    Anampa-Guzman, Andrea Carolina
    Alharbi, Malak
    Shalaby, Khalid
    Patel, Riya
    Hamid, Showkat
    George, Anthony
    Attwood, Kristopher
    Hernandez-Ilizaliturri, Francisco J.
    Cortese, Matthew J.
    BLOOD, 2023, 142
  • [3] ASPEN: Results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom Macroglobulinemia (WM)
    Buske, C.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H-P
    Cull, G.
    Owen, R. G.
    Marlton, P.
    Wahlin, B. E.
    Garcia, Sanz R.
    McCarthy, H.
    Mulligan, S.
    Tedeschi, A.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Leblond, V
    Chan, W. Y.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 107 - 108
  • [4] ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM)
    Tedeschi, A.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H.
    Cull, G.
    Owen, R.
    Marlton, P.
    Wahlin, B.
    Garcia Sanz, R.
    McCarthy, H.
    Mulligan, S.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Buske, C.
    Leblond, V.
    Chan, W.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C.
    HAEMATOLOGICA, 2021, 106 (10) : 9 - 10
  • [5] Familial characteristics of Waldenstrom's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL):: A population-based study in Sweden
    Kristinsson, S. Y.
    Bjorkholm, M.
    Goldin, L. R.
    McMaster, M. L.
    Turesson, I.
    Landgren, O.
    ANNALS OF ONCOLOGY, 2008, 19 : 166 - 166
  • [6] Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.
    Chen, C. I.
    Kouroukis, T.
    White, D.
    Voralia, M.
    Stadtmauer, E.
    Wright, J.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 432S - 432S
  • [7] Rituximab for Waldenstrom's macroglobulinemia (WM) (E3A98): An ECOG phase II pilot study for untreated or previously treated patients.
    Gertz, MA
    Rue, M
    Blood, E
    Kaminer, LS
    Vesole, DH
    Greipp, PR
    BLOOD, 2003, 102 (11) : 148A - 148A
  • [8] Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Zimmerman, Ashley
    Heslop, Keisha
    Chapin, Dustin
    Sher, Taimur
    Roy, Vivek
    Rasheed, Ahsan
    Paulus, Aneel
    Chanan-Khan, Asher
    BLOOD, 2022, 140 : 9331 - 9332
  • [9] ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM).
    Tam, Constantine Si Lun
    Opat, Stephen
    D'Sa, Shirley
    Jurczak, Wojciech
    Lee, Hui-Peng
    Cull, Gavin
    Owen, Roger G.
    Marlton, Paula
    Wahlin, Bjorn E.
    Tedeschi, Alessandra
    Castillo, Jorge J.
    Siddiqi, Tanya
    Buske, Christian
    Leblond, Veronique
    Chan, Wai Y.
    Schneider, Jingjing
    Ro, Sunhee K.
    Cohen, Aileen
    Huang, Jane
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] JS']JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma3. Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia (LPL/WM)
    Yoshida, Isao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
12345